{"id":"NCT00266630","sponsor":"Eli Lilly and Company","briefTitle":"Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder","officialTitle":"Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2009-05","completion":"2009-05","firstPosted":"2005-12-19","resultsPosted":"2010-06-29","lastUpdate":"2010-12-28"},"enrollment":139,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Manic or Mixed Episode Associated With Bipolar I Disorder"],"interventions":[{"type":"DRUG","name":"olanzapine","otherNames":["LY170053","Zyprexa"]},{"type":"DRUG","name":"lithium","otherNames":[]},{"type":"DRUG","name":"valproate","otherNames":[]},{"type":"DRUG","name":"carbamazepine","otherNames":[]}],"arms":[{"label":"Olanzapine Monotherapy","type":"EXPERIMENTAL"},{"label":"Olanzapine + Mood Stabilizer","type":"EXPERIMENTAL"}],"summary":"The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC \\[Study BMAC\\]) will be examined.","primaryOutcome":{"measure":"Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only","timeFrame":"baseline through 18 weeks","effectByArm":[{"arm":"Olanzapine Monotherapy","deltaMin":-3,"sd":5.6}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":11,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":100},"commonTop":["Nasopharyngitis","Somnolence","Weight increased","Blood triglycerides increased","Depressive symptom"]}}